Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Caisson aims to unload HEPtune platform
October 2016
SHARING OPTIONS:

AUSTIN, Texas—Caisson Biotech LLC has tapped Pickwick Capital Partners in its efforts to sell its proprietary HEPtune drug-delivery platform, which features a strong U.S. and international patent portfolio. The platform is focused on the use of heparosan, a naturally occurring sugar polymer, and has been proven in hemophilia.
 
“Caisson’s HEPtune platform has been demonstrated to improve proteolytic activity and half-life for hemophilia Factor VII compared to unconjugated FVII or FVII conjugated with polyethylene glycol (PEG). Additionally, HEPtune enables new patent protection for drug conjugates, can lower costs and reduce the growing concern of immunogenicity with PEG conjugates,” said Paul Bundschuh, a managing director at Pickwick Capital Partners. “Many therapeutic protein market opportunities exist that could benefit from HEPtune. Pickwick is excited to leverage our life-sciences/biotech team of experienced bankers and subject-matter experts to help Caisson find the ideal buyer/s.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.